Plasma Fractionation Market 2017 : Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis And Competitive Analysis 2025

The global plasma fractionation market is categorized on the basis of product type, application, end user and regional. On the basis of product the market is divided into albumin, coagulation factor concentrates immunoglobulin, protease inhibitor and other plasma products.

Plasma fractionation is process of separation of plasma protein which is in turn components of blood derived by blood fractionation. Plasma is collected from donor when whole blood is donated or by process called plasmapheresis in which liquid part of the blood is separated from the blood cells and plasma is retained. The important function of plasma fractionation is to remove or inactivate the viruses an  d prions present in the blood. These fractionated human plasma proteins are essential class of therapeutics applied in prevention, management and treatment of life-threating conditions resulting from trauma, immunologic disorders, congenital deficiencies or various other infections. Plasma comprises of thousands of proteins, of them only about 20 used as natural starting material for the production of biological drugs.  These broadly considered under three classes. Albumin, immunoglobulin’s and clotting factor.

To Get Sample Copy of Report visit @

Market Growth Factors

Growing use of immunoglobulin’s in healthcare application and increased prevalence of respiratory diseases such as emphysema and AATD are factors propelling the market growth. Furthermore,   plasma usage in the production of packaging material for industrial application and its demand in therapeutic area for treating protein deficiencies fuelling the market for further growth.  However, emergence for recombinant alternative, high initial cost investment and limited reimbursement issues limits the market expansion that might hamper the market growth.


The global plasma fractionation market is categorized on the basis of product type, application, end user and regional. On the basis of product the market is divided into albumin, coagulation factor concentrates immunoglobulin, protease inhibitor and other plasma products.  Immunoglobulin product of plasma fractionation dominates the market owing to wider acceptance of immunoglobulin in diverse neurological & immunological disorders and growing adoption of subcutaneous immunoglobulins. Protease inhibitor is anticipated grow at high speed mainly attributing to increase in different respiratory disease and prevalence of alpha-1 antitrypsin deficiency.  Depending upon application the market is segment into neurology, immunology, haematology, pulmonology, critical care, heamto-ocology, rheumatology and other application. Considering end user the world plasma fractionation market is separated into academic institutes, clinical research laboratories and hospitals & clinics. Hospital & clinic segment is expected to grow lucratively in coming years as number of patient visiting hospital and high usage of plasma products for treating various diseases. 

Regional Analysis

Based on geography, the global plasma fractionation market is analysed across North America, Europe, Asia-Pacific and LAMEA. North America holds the largest share of the market. The factors attributing the largest share of this market are increased expenditure on healthcare per capita, increased demand of patients for advanced healthcare facilities and rising use of prophylaxis treatment for diagnosed patient. Asia-Pacific is anticipated to witness the growth in coming years mainly owing to increased prevalence of haemophilia, growing geriatric population and prevalence of different diseases in that particular region.

Check Discount on this report @

Competitive Analysis

The top players in global plasma fractionation market are CSL, Octapharma AG, Grifols S.A, Kedrion S.p.A, Shire, Bio Product Laboratory, Sanquin, Biotest, LFB, and Japan Blood Products Organization.

Latest News

On November 21st 2017, Octapharma a renowned human protein products manufacturer company in collaboration with project SHARE donated 30.5 million international units of recombinant factor VIII product Nuwiq® derived from human cell line. Project SHARE is humanitarian programme provides blood clotting factor in developing country where factor is unavailable or scarce. This blood clotting factor Nuwiq®    plays majorly important function in factor replacement therapy in people suffering with haemophilia.

About Garner Insights:
Garner Insights ( is a Market Intelligence and Business Consulting firm led by professionals with a vast experience and knowledge of the market research industry.

Our vast repository of research reports across various categories, gives you a complete view of the ever-evolving trends and current topics worldwide. Our constant focus is on improving the data and finding innovative methods, which will help your business drive profitable growth.The research methodology is designed to cater all your research needs which is backed by exclusive quantitative and analytics driven intelligence. It consists of primary and secondary methods which is a testimony of the information comprised. The meticulous and distinct data gathering methods are in line with the highest standards of data mining in the industry.

Mr. Kevin Thomas
Garner Insights
+1 513 549 5911 (US)

+44 203 318 2846 (UK)
Email –

Media Contact
Company Name: Garner Insights
Contact Person: Kevin Thomas
Phone: +1 513 549 5911
City: Pune
Country: India